CLAIMS

1. Compound mixture comprising the following compounds a) and b):

a) (S)-3-Hydroxy-1-(1H-indol-5-yl)-2-oxo-pyrrolidine-3-carboxylic acid 3,5-difluoro-benzylamide or a physiologically acceptable salt thereof;

b) an inhibitor of one or more of VEGFR1, VEGFR2, VEGFR3 and VEGF, or a physiologically acceptable salt thereof.

2. Compound mixture according to claim 1, wherein the inhibitor is selected from the group consisting of aflibercept, apatinib, axitinib, bevacizumab, brivanib alaninate, cabozantinib, cediranib, lenvatinib, linifanib, pazopanib, ponatinib, ramucirumab, regorafenib, sorafenib, sunitinib, vandetanib, and 33C3.

3. Compound mixture according to claim 1 or 2, wherein the inhibitor is cabozantinib or axitinib.

4. Compound mixture according to any one of claims 1 to 3, wherein the inhibitor is cabozantinib.

5. Compound mixture according to any one of claims 1 to 4, wherein compound b) is cabozantinib (S)-malate.

6. Compound mixture according to any one of claims 1 to 3, wherein the inhibitor is axitinib.

7. Pharmaceutical composition comprising a compound mixture according to any one of claims 1 to 6 and, optionally, further comprising one or more excipient(s) and/or adjuvant(s).

8. Kit comprising separate packs of the following compounds a) and b):

a) (S)-3-Hydroxy-1-(1H-indol-5-yl)-2-oxo-pyrrolidine-3-carboxylic acid 3,5-difluoro-benzylamide or a physiologically acceptable salt thereof;

b) an inhibitor of one or more of VEGFR1, VEGFR2, VEGFR3 and VEGF, or a physiologically acceptable salt thereof.

9. Kit according to claim 8, wherein the inhibitor is selected from the group consisting of aflibercept, apatinib, axitinib, bevacizumab, brivanib alaninate, cabozantinib, cediranib, lenvatinib, linifanib, pazopanib, ponatinib, ramucirumab, regorafenib, sorafenib, sunitinib, vandetanib, and 33C3.

10. Kit according to claim 8 or 9, wherein the inhibitor is cabozantinib or axitinib.

11. Kit according to any one of claims 8 to 10, wherein the inhibitor is cabozantinib.

12. Kit according to any one of claims 8 to 11, wherein compound b) is cabozantinib (S)-malate.

13. Kit according to any one of claims 8 to 10, wherein the inhibitor is axitinib.

~~14. Method for prophylaxis or treatment of cancer, the method comprising administering to a subject the following compounds a) and b):~~

~~a) (S)-3-Hydroxy-1-(1H-indol-5-yl)-2-oxo-pyrrolidine-3-carboxylic acid 3,5-difluoro-benzylamide or a physiologically acceptable salt thereof;~~

~~b) an inhibitor of one or more of VEGFR1, VEGFR2, VEGFR3 and VEGF, or a physiologically acceptable salt thereof.~~

~~15. Method according to claim 14, wherein the inhibitor is selected from the group consisting of aflibercept, apatinib, axitinib, bevacizumab, brivanib alaninate, cabozantinib, cediranib, lenvatinib, linifanib, pazopanib, ponatinib, ramucirumab, regorafenib, sorafenib, sunitinib, vandetanib, and 33C3.~~

~~16. Method according to claim 14 or 15, wherein the inhibitor is cabozantinib or axitinib.~~

~~17. Method according to any one of claims 14 to 16, wherein the inhibitor is cabozantinib.~~

~~18. Method according to any one of claims 14 to 17, wherein compound b) is cabozantinib (S)-malate.~~

~~19. Method according to any one of claims 14 to 16, wherein the inhibitor is axitinib.~~

~~20. Method according to any one of claims 14 to 19, wherein the cancer is a cancer for which the inhibitor is a standard-of-care treatment option and/or a cancer susceptible to anti-angiogenic treatments.~~

~~21. Method according to any one of claims 14 to 20, wherein the cancer is selected from a group consisting of renal-cell carcinoma, colorectal cancer, lung cancer, head and neck cancer, gastric cancer, gastro-esophageal junction adenocarcinoma, gastrointestinal stromal tumors, glioblastoma, hepatocellular carcinoma, breast cancer, thyroid cancer, soft tissue sarcoma, chronic myeloid leukemia, and Philadelphia chromosome positive acute lymphoblastic leukemia.~~

~~22. Method according to any one of claims 14 to 21, wherein the cancer is renal cell carcinoma.~~

~~23. Method according to claim 22, wherein the renal cell carcinoma is clear cell renal cell carcinoma.~~

~~24. Method according to any one of claims 14 to 23, wherein compounds a) and b) are administered simultaneously.~~

~~25. Method according to any one of claims 14 to 23, wherein compounds a) and b) are administered sequentially.~~

~~26~~14. Compounds a) and b) for use in a method of prophylaxis or treatment of cancer, wherein the method comprises administering to a subject the compounds a) and b), and wherein the compounds a) and b) are:

a) (S)-3-Hydroxy-1-(1H-indol-5-yl)-2-oxo-pyrrolidine-3-carboxylic acid 3,5-difluoro-benzylamide or a physiologically acceptable salt thereof;

b) an inhibitor of one or more of VEGFR1, VEGFR2, VEGFR3 and VEGF, or a physiologically acceptable salt thereof.

~~27~~15. Compounds a) and b) for the use according to claim ~~26~~14, wherein the inhibitor is selected from the group consisting of aflibercept, apatinib, axitinib, bevacizumab, brivanib alaninate, cabozantinib, cediranib, lenvatinib, linifanib, pazopanib, ponatinib, ramucirumab, regorafenib, sorafenib, sunitinib, vandetanib, and 33C3.

~~28~~16. Compounds a) and b) for the use according to claim ~~26~~ 14 or ~~27~~15, wherein the inhibitor is cabozantinib or axitinib.

~~29~~17. Compounds a) and b) for the use according to any one of claims ~~26~~ 14 to ~~28~~16, wherein the inhibitor is cabozantinib.

~~30~~18. Compounds a) and b) for the use according to any one of claims ~~26~~ 14 to ~~29~~17, wherein compound b) is cabozantinib (S)-malate.

~~31~~19. Compounds a) and b) for the use according to any one of claims ~~26~~ 14 to ~~28~~16, wherein the inhibitor is axitinib.

~~32~~20. Compounds a) and b) for the use according to any one of claims ~~26~~ 14 to ~~31~~19, wherein the cancer is a cancer for which the inhibitor is a standard-of-care treatment option and/or a cancer susceptible to anti-angiogenic treatments.

~~33~~21. Compounds a) and b) for the use according to any one of claims ~~26~~ 14 to ~~32~~20, wherein the cancer is selected from a group consisting of renal-cell carcinoma, colorectal cancer, lung cancer, head and neck cancer, gastric cancer, gastro-esophageal junction adenocarcinoma, gastrointestinal stromal tumors, glioblastoma, hepatocellular carcinoma, breast cancer, thyroid cancer, soft tissue sarcoma, chronic myeloid leukemia, and Philadelphia chromosome-positive acute lymphoblastic leukemia.

~~34~~22. Compounds a) and b) for the use according to any one of claims ~~26~~ 14 to ~~33~~21, wherein the cancer is renal cell carcinoma.

~~35~~23. Compounds a) and b) for the use according to claim ~~34~~22, wherein the renal cell carcinoma is clear cell renal cell carcinoma.

~~36~~24. Compounds a) and b) for the use according to any one of claims ~~26~~ 14 to ~~35~~23, wherein compounds a) and b) are to be administered simultaneously.

~~37~~25. Compounds a) and b) for the use according to any one of claims ~~26~~ 14 to ~~35~~23, wherein compounds a) and b) are to be administered sequentially.

~~38~~26. Compound mixture according to any one of claims 1 to 6, or pharmaceutical composition according to claim 7, for use in a method of prophylaxis or treatment of cancer~~, wherein the method is the method according to any one of claims 14 to 25~~.

~~39~~27. Use of compounds a) and b) for the manufacture of a medicament for prophylaxis or treatment of cancer, wherein compounds a) and b) are:

a) (S)-3-Hydroxy-1-(1H-indol-5-yl)-2-oxo-pyrrolidine-3-carboxylic acid 3,5-difluoro-benzylamide or a physiologically acceptable salt thereof;

b) an inhibitor of one or more of VEGFR1, VEGFR2, VEGFR3 and VEGF, or a physiologically acceptable salt thereof.

~~40~~28. Use of a compound mixture according to any one of claims 1 to 6 or a pharmaceutical composition according to claim 7 for the manufacture of a medicament for prophylaxis or treatment of cancer.